Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment (LLCRlowdoz)
Chronic Lymphocytic Leukemia (CLL) is still an incurable disease. However recent advances have established correlation between the quality of the response (in particular achievement of negativity of minimal residual disease (MRD) and progression free and overall survival. That is why MRD negative complete remission (CR) is the current goal in CLL treatment.
The association of Rituximab fludarabine cyclophosphamide leads to the best response rate with 52 to 72% CR in "medically" fit untreated CLL patients. MRD results in this setting are still preliminary and around 50%. However many other situations (unfit, elderly, relapse, haematological toxicity leading to early interruption of treatment…) are associated with much lower response rate that would be improved by consolidation treatment.
Monoclonal antibodies are the treatment of choice for consolidation because of sparing marrow and targeting CLL cells. Alemtuzumab has been used for this purpose and results confirm improvement of CR and MRD negative responses but alemtuzumab induced immunodeficiency lead to unacceptable infectious complications. Rituximab monotherapy induces low response rate at standard dose regimen. This is at least partially due to shaving of CD20, mechanism by which CD20 is lost from the leukemic cells but these cells are not cleared. Using low doses of rituximab reduced shaving and allowed CLL cells clearance by the mononuclear phagocytic system. Such low doses of rituximab can be administered subcutaneously.
The investigators then propose subcutaneous low dose rituximab in consolidation to CLL patients responding after induction but having not achieved MRD negative CR.
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase II Study of Tolerance and Efficacy of Subcutanous Low Doses Rituximab Given as Consolidation Treatment to Chronic Lymphocytic Leukaemia (CLL) Patients Responding to Induction Therapy|
- Residual disease [ Time Frame: up to 3 month after the end of treatment ] [ Designated as safety issue: No ]- minimal residual disease (MRD) negative complete response (CR) rate after consolidation using subcutaneous low dose of rituximab, from randomisation up to 3 month after the end of treatment
- overall survival [ Time Frame: From date of inclusion until date of death, assessed up to 10 years ] [ Designated as safety issue: No ]time between inclusion and death
- Adverse events [ Time Frame: up to 3 months ] [ Designated as safety issue: Yes ]Number and description of adverse events recorded according to the CTC-AE V4
- -Quality of life [ Time Frame: up to 3 months after the end of treatment ] [ Designated as safety issue: No ]-Quality of life study by QLQ-C30
- Immune functions [ Time Frame: up to 3 months after the end of treatment ] [ Designated as safety issue: No ]NK, monocytes, CD8, and CD 20 expression on leucemic cells or B cells
- - Progression free survival [ Time Frame: up to time of progression assessed up to 10 years ] [ Designated as safety issue: No ]Time between inclusion and progression
- treatment free survival [ Time Frame: up to time of new treatment assessed up to 10 years ] [ Designated as safety issue: No ]time between end of treatment and restarting a new treatement
|Study Start Date:||December 2011|
|Estimated Study Completion Date:||June 2015|
|Estimated Primary Completion Date:||June 2015 (Final data collection date for primary outcome measure)|
Consolidation treatment with sub cutaneaous low doses of Rituximab
Low doses of sub cutaneaous rituximab
Other Name: Rituximab
Objective(s) of the clinical study
- To improve the minimal residual disease (MRD) negative complete response (CR) rate after consolidation using subcutaneous low dose of rituximab
- Progression free survival, treatment free survival, overall survival,
- MRD follow-up,
- Medico-economic study
- Quality of life study
- Immune functions study (ancillary study)
Main assessment criteria:
MRD negative CR rate, established by peripheral blood 4colour flow cytometry according to international consensus on CLL MRD study, at the end of the consolidation treatment.
Inclusion of patients after the evaluation of response to induction treatment according to NCI-ICLLWG criteria and MRD analysis (2 to 3 months after induction completion): patients having not achieved MRD negative CR.
Consolidation treatment by subcutaneous rituximab given at 20 mg/m²/d thrice weekly during 12 weeks.
Evaluation of the response 3 months after completion of the consolidation treatment.
Subjects number: 35 patients will be needed to accept the hypothesis of an augmentation of CR with negative MRD >=40%, excluding the hypothesis that this rate is < 20%. This ensure us an alpha risk at 5% with a 80% power, taking into account that non evaluable patients will be < 5%.
Brief description of the ancillary study:
Immune functions study before and after consolidation treatment by rituximab
Please refer to this study by its ClinicalTrials.gov identifier: NCT01521689
|Contact: Dominique GENRE, MD||33 4 91 22 37 email@example.com|
|Contact: Agnès BOYER CHAMMARD, MD||33 4 91 22 37 firstname.lastname@example.org|
|Institut Paoli Calmettes||Recruiting|
|Marseille, France, 13009|
|Contact: Thérèse AURRAN, MD 33491223778 email@example.com|
|Principal Investigator:||Thérèse AURRAN, MD||Institut Paoli-Calmettes|